Answers are grounded in this paper and cite their sources.
To investigate the therapeutic potential of 4-Octyl itaconic acid (4-OI), a derivative of the endogenous immunomodulator itaconate (ITA), as a safe and effective anti-inflammatory agent for the treatment of dry eye disease (DED). In vitro cytotoxicity and anti-inflammatory effects of 4-OI were evaluated in hyperosmotic human corneal epithelial cells (HCEC). An in vivo DED model was induced in C57BL/6 mice through environmental controlled chambers. Mice with DED were treated with PBS, 0.05% cyclosporine A (CsA) eye drops, 4-OI eye drops, or a single 4-OI intraperitoneal injection for 14 days. Corneal epithelial defects and tear secretion were assessed. The safety and underlying molecular mechanisms of topical 4-OI were evaluated using quantitative PCR (qPCR), Western blotting (WB), mRNA sequencing, TUNEL assay, and H&E staining. Statistical analyses were performed using independent sample t-tests and one-way ANOVA, with P < 0.05 considered statistically significant. Treatment with 4-OI eye drops significantly reduced corneal epithelial defects in DED mice ( P < 0.0001) compared to the DED control group. Tear secretion was also elevated in the 4-OI eye drop-treated groups. mRNA sequencing revealed significant downregulation of inflammatory pathways, including IL-1 receptor activity, TNF signaling, and IL-17 signaling, in the 2 mM 4-OI eye drop group. Molecular assays confirmed a marked reduction in the mRNA and protein expression of IL-1β, IL-17A, TNF-α, and NFKBIZ (IκBζ) in the corneas of 4-OI-treated mice. No significant corneal epithelial apoptosis or systemic toxicity was observed in the 4-OI-treated groups. The ITA derivative 4-OI demonstrates potential as a safe and effective therapeutic option for alleviating dry eye disease by suppressing ocular inflammation through the downregulation of IL-1, IL-17, and TNF signaling pathways. • First evidence: 4-OI eye drops reduce dry eye pathology in murine models. • Novel mechanism: 4-OI downregulates IL-1/IL-17/TNF pathways in cornea. • Topical 4-OI efficacy matches cyclosporine A, suggesting therapeutic potential. • 4-OI eye drops show excellent corneal safety and tolerability profile.
No takes yet. Share an insight, caveat, or question.
Zhai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: